Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
- SBS Transfers Tagamet to Sumitomo
January 15, 2001
- NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
- SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
- Sankyo to Codevelop Oral Antithrombotic with Lilly
January 1, 2001
- Long-term Administration of PPI Included in Insurance Coverage
January 1, 2001
- Aiming at Sales of ¥350 Bil. to ¥400 Bil. in 2005: Mr Bootes of Pfizer
January 1, 2001
- Mitsubishi-Tokyo Licenses Antiviral Agent MCC-478 to Eli Lilly
January 1, 2001
- Third Parties to Be Allowed to Provide Sperm or Ova for Infertile Couples
January 1, 2001
- Taisho Licenses CRF Receptor Antagonist to Janssen
January 1, 2001
- Serious Skin Disorders Caused by Drugs Reported: PMSB
January 1, 2001
- BMS Creates Bristol Pharmaceuticals, Spliting Off Its Pharm. Div.
January 1, 2001
- Promotion of Genomic Research Recommended by Deregulation Panel
January 1, 2001
- BASF Sells Pharma Business to Abbott
January 1, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
- Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
- Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
- JPMA to Work More Closely with Patients' Organizations
January 1, 2001
- Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
- Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…